Rep. Glenn Grothman

Maddy summaryThis bill allows groups of small businesses or self-employed individuals to form a single health plan that treats all members as one employer for coverage purposes. It directly affects small business associations and self-employed people who can join such groups to access pooled health coverage, provided they meet specific requirements (e.g., 51+ total employees, 2+ years in existence, no health-based discrimination). Key mechanisms include permitting modified community rating for premiums (based on pooled claims) while prohibiting health status-related discrimination in enrollment, premiums, or pre-existing condition coverage. The plan remains subject to federal ERISA rules, and self-employed members must meet defined criteria to participate as both employers and employees.

Maddy summaryHR 2571, the Self-Insurance Protection Act, clarifies that stop-loss insurance purchased by self-funded employer health plans is not considered "health insurance coverage" under federal law. It directly affects employers (both large and small) who self-fund health benefits for their employees, as these employers use stop-loss insurance to protect their company assets from unexpected, high medical claims costs. The bill amends ERISA to exempt this stop-loss coverage from state health insurance regulations and ensures federal law preempts any state laws that might block employers from using this protection. This change aims to maintain the availability of stop-loss insurance as a key risk management tool for self-funded health plans.

Miracle on Ice Congressional Gold Medal Act This act provides for the award of Congressional Gold Medals to the members of the 1980 U.S. Olympic men's ice hockey team in recognition of the team's achievement at the 1980 Winter Olympic Games.

Maddy summaryThe SHIELD Act of 2025 withholds federal funding from states or local governments that arrest, detain, or prosecute federal officers for lawful immigration enforcement actions. It directly affects jurisdictions (like cities or counties) that interfere with federal immigration enforcement, such as by blocking ICE operations. The law requires the Attorney General and DHS to determine violations, then blocks all federal grants and contracts for the affected jurisdiction during the fiscal year. Funding withheld is reallocated to compliant jurisdictions, and restoration requires written assurances that interference will stop.

Skinny Labels, Big Savings Act This bill provides a statutory safe harbor from patent infringement claims for generic or biosimilar manufacturers that seek or obtain approval for skinny labels of their drugs. Under current law, the Food and Drug Administration (FDA) may approve generic and biosimilar drugs through a process known as skinny labeling, which allows a generic manufacturer to seek approval only for approved uses of the drug that are no longer protected by patents. However, in GlaxoSmithKline LLC v. Teva Pharmaceuticals USA, Inc. , a court held that a generic manufacturer may sometimes be liable for patent infringement when it markets skinny label generics. The bill specifically lists the following as actions that are not considered infringement of a method of use claim in a patent under the Federal Food, Drug, and Cosmetic Act: submitting or seeking approval of a skinny label for a generic or biosimilar drug; promoting or commercially marketing a drug with skinny labeling approved by the FDA; or describing a drug product approved by the FDA as a generic of, or therapeutically equivalent to, the branded drug. The bill also applies the safe harbor to similar actions under the Public Health Service Act.

Maddy summaryHR 6475, the Preventing Child Trafficking Act of 2025, requires the Department of Justice's Office for Victims of Crime and the Administration for Children and Families' Office on Trafficking in Persons to implement the 2023 Government Accountability Office's recommendations for preventing child trafficking and supporting survivors. The bill mandates these agencies to collaborate using established best practices, develop measurable performance goals for child trafficking programs, and base these targets on existing grantee data. It directly affects federal agencies managing anti-trafficking programs and the children and survivors served by those programs. The bill requires a report to Congress within 180 days detailing how these implementation steps were carried out.

Maddy summaryThe Freedom to Heal Act of 2025 creates a new federal registration process for physicians to directly administer Schedule I investigational drugs under the "Right to Try" framework. It requires physicians to apply to the Attorney General with evidence of state compliance, manufacturer agreements, and training, and limits the amount of drugs they may possess based on approved applications. The bill mandates the Attorney General to issue interim rules within 240 days and final rules within two years covering drug delivery, storage, recordkeeping, and registration management. This affects physicians treating eligible patients with Schedule I drugs under federal Right to Try provisions, not the patients themselves.

Maddy summaryThis bill requires IRS employees to obtain written approval from a supervisor before sending any penalty notice to a taxpayer. It modifies the Internal Revenue Code to mandate that an IRS official’s immediate supervisor (the person they report to) must personally approve penalty assessments in writing before any penalty communication is sent. The rule applies to all penalties issued after December 31, 2025. This directly affects taxpayers who face IRS penalty notices, adding a review step before penalties are formally proposed or imposed.

Give Kids a Chance Act of 2025 This bill expands the Food and Drug Administration’s (FDA’s) authority with respect to research on rare pediatric diseases, including by permitting the FDA to take enforcement action against drug sponsors that fail to satisfy pediatric study requirements and by reauthorizing programs that support pediatric research.  Specifically, the bill modifies requirements relating to molecularly targeted pediatric cancer investigations to permit research on new drugs in combination with active ingredients that have already been approved, provided certain conditions are met; permits the FDA to take enforcement action against drug sponsors that fail to comply with pediatric study requirements, if such sponsors demonstrated a lack of due diligence in satisfying the requirement; renews the FDA’s authority to award priority review vouchers to sponsors of new products intended to treat rare pediatric diseases through September 30, 2029; and reauthorizes through FY2027 certain funding for the National Institutes of Health to support priority pediatric research.  The bill also provides statutory authority for the FDA’s interpretation of the orphan drug exclusivity period. The bill specifies, consistent with FDA regulations, that the seven-year market exclusivity period for drugs for rare diseases or conditions (i.e., orphan drugs) prohibits the approval of the same drug for the same approved use or indication with respect to the disease or condition. (In Catalyst Pharmaceuticals, Inc. v. Becerra , a court rejected the FDA’s interpretation and held that orphan drug exclusivity extends to all uses or indications for the disease or condition.)

Maddy summaryThis bill denies immigration benefits to individuals who participated in, supported, or facilitated Hamas attacks against Israel starting October 7, 2023. It amends immigration law to make such individuals inadmissible (barred from entering the U.S.) and ineligible for any immigration relief, including asylum or other protections. The law requires annual reports from the Homeland Security Secretary tracking how many people are denied entry or removed under these provisions. It directly affects non-U.S. nationals involved in Hamas-related violence against Israel since the October 7, 2023, attacks.